SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
BOLT

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$4.91-$0.15 (-2.96%)
 
Market cap
$12.8M
Insider Score
Health Score
Analyst consensus
Listed since
Feb 5, 2021
Market Cap$12.80M+3.6%
Revenue (ttm)$2.53M-51.3%
Net Income-$26.02M+39.0%
EPS-$14.53-63.4%
Shares Out2.61M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend DateAug 29, 2014
Volume60,465
Open$5.10
Previous Close$5.06
Day's Range$4.88 - $5.21
52-Week Range$3.10 - $7.78
Beta1.01
AnalystsHold
Price Target$4.00(-18.53%)
Earnings DateMar 11, 2027
-2.77% (1D)
No price history available.

About BOLT

Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.

Address
900 Chesapeake Drive, Redwood City, CA, 94063, US
Market Cap
13 million
Employees
23
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$128.28K
Bought
$635.89K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Weak
From BOLT’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-2.96%
5 Days
-18.03%
1 Month
+18.60%
6 Months
+6.97%
1 Year
+3.59%

$BOLT stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in BOLT holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by BOLT's directors and management

Net Shares Purchased by Insiders−200k−100k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

BOLT Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New BOLT patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to BOLT from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in BOLT

VXFVanguard Extended Market ETF$46.53K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from BOLT’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
60
News & Sentiment
20% of score
45

News check: Q3 results reported but limited detail provided; insufficient coverage to assess whether results beat or missed expectations.

Recent Insider Activity

Buys
9
Sells
9
Buy Value
$635.89K
Distinct Buyers
3

Insider Score Trend Over Time

+0.0 since Sep 22
0255075100Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 37.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Sep 22Sep 28Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.